FOLH1 and metastatic prostate carcinoma: In summary, our data suggests that PSMA PET imaging strongly surpassed ctDNA in its discovery efficacy for PCa [9] across the whole spectrum of disease, in line with previous reports of PSMA PETs’ high sensitivity in detecting tumor lesions and low abundance of ctDNA in low-volume [23] and non-metastatic prostate cancer [22], indicating that ctDNA analysis might be most applicable in the setting of metastatic CRPC in the future.